Close Menu

NEW YORK – Veracyte said after the close of the market on Thursday that it expects preliminary Q1 revenues to be in the range of $30.5 million to $31.5 million.

The expected revenues would represent a range of 3 to about 7 percent increase from $29.5 million a year ago and would beat the analysts' average estimate of $30.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.